Full Press Release Details
WESTLAKE VILLAGE, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) --Arcutis Biotherapeutics, Inc.(Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced results ofSkin Insights: Steroid Perceptions in Chronic Inflammatory Skin Diseases, a nationwide survey of adults and parents of children with plaque psoriasis, atopic dermatitis (the most common form of eczema), and seborrheic dermatitis. The survey was designed to understand patient and parent perceptions and behaviors around the use of topical steroids, as well as perspectives on short-term, reactive treatments versus long-term, proactive disease management.
“Psoriasis is a chronic disease that requires lifelong management — and much the same could be said of seborrheic dermatitis and eczema. This survey highlights an important trend: most treatment plans still focus on a reactive approach focused on taming flares, instead of a proactive, long-term disease management strategy to prevent flares. What’s more, these results demonstrate that even when symptoms are well controlled, many adults and children live with an undercurrent of worry in anticipation of the inevitable next flare. This persistent emotional strain is part of the hidden burden of chronic skin diseases,” said Leah M. Howard, JD, president and chief executive officer of the National Psoriasis Foundation. “These findings suggest a pivotal opportunity for adults and parents of children with psoriasis and other chronic inflammatory skin diseases to explore safe, effective non-steroidal treatment alternatives with their healthcare provider.”
Key findings ofSkin Insights: Steroid Perceptions in Chronic Inflammatory Skin DiseasesAdults and parentsof children with plaque psoriasis, eczema, and seborrheic dermatitis suffer from frequent, uncontrolled flare cycles and treatment plans that still focus on treating a flare after it has occurred.The survey of 1,000 adults and 500 parents demonstrated:
Concern and uncertainty with steroid use remainTopical steroids are by far the most commonly prescribed topical prescription for these conditions. All survey respondents had been prescribed at least one topical steroid to treat their or their child’s condition at one point in their lives, and the majority (67% of adults and 57% of parents) were prescribed at least one topical steroid to treat their/their child's condition in the last year. Critically, the survey showed:
The “cycle of flares” goes far beyond the visible impact to the skin, resulting in substantial emotional, mental, and daily life challenges.According to the survey:
“For the more than 46 million Americans living with atopic dermatitis, seborrheic dermatitis, and plaque psoriasis, these insights have serious everyday implications. This research confirms and builds on a growing body of data indicating the marked social, mental, and emotional burden experienced by adults and children with skin conditions like eczema and seborrheic dermatitis. The combined effect of missing school, avoiding friends, and missing sports could have long-term social consequences and emphasizes the need for treatment plans that focus on proactive disease management as a long-term solution," said Wendy Smith Begolka, MBS, chief program and mission officer, National Eczema Association.
Despite disease being under control, worry and lack of confidence remain.
“There’s a growing consensus across the dermatology community that long-term use of topical steroids can carry serious local as well as systemic risks, and there is a desire to move away from episodic care towards more proactive disease management,” said Patrick Burnett, MD, PhD, FAAD, chief medical officer at Arcutis. “These survey findings highlight the real-world challenges adults and parents of children with these conditions face in managing chronic skin diseases and reinforce the need for treatment options that go beyond cyclical care and deliver effective, sustained relief — underscoring the urgent need to redefine what standard of care should look like.”
Click to view full survey infographic
About the SurveyThe online survey was conducted by Wakefield Research on behalf of Arcutis Biotherapeutics, and in collaboration with the National Eczema Association and the National Psoriasis Foundation, among:
The survey was conducted in August and September 2025.
About ArcutisArcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing portfolio of advanced targeted topicals approved to treat three major inflammatory skin diseases. Arcutis’ unique dermatology development platform, coupled with our dermatology expertise, allows us to develop differentiated therapies against biologically validated targets, and has produced a robust pipeline for a range of inflammatory dermatological conditions. For more information, visitwww.arcutis.comor follow Arcutis onLinkedIn,Facebook,Instagram, andX.
Contacts:MediaAmanda Sheldon, Head of Corporate Communicationsmedia@arcutis.com
InvestorsBrian Schoelkopf, Head of Investor Relationsir@arcutis.com
A photo accompanying this release will be available athttps://www.globenewswire.com/NewsRoom/AttachmentNg/ab84d935-4a78-4034-bcd7-b8e7440fa229